So here's what happens when you miss earnings and give weak guidance: your stock goes down. That's the simple story for Harrow Inc. (HROW) today, as shares of the eye disease medicine maker are getting pummeled in premarket trading.

The company reported fourth quarter earnings of 17 cents per share, which sounds fine until you realize analysts were expecting 38 cents. That's a pretty big miss. The revenue side was better—sales jumped from $66.81 million to $89.09 million, actually beating the consensus estimate of $88.45 million. But investors are clearly focusing on the bottom line miss and what comes next.

And what comes next, according to Harrow's guidance, is fiscal 2026 sales of $350 million to $365 million. The problem? Wall Street was looking for $386.26 million. When you guide below expectations, the market tends to punish you, even if your current quarter revenue was strong.

During the quarter, Harrow also recorded $8.5 million in acquired in-process research and development expenses related to its acquisition of Melt Pharmaceuticals. That's the kind of investment that might pay off later, but doesn't help earnings today.

Management's Sunny Outlook vs. Market's Cloudy View

CEO Mark Baum is trying to paint a brighter picture. "I also believe we are going to provide positive surprises this year (and next) with a few products in our portfolio that haven't received much attention," Baum said. "With multiple growth drivers gaining traction and a larger commercial footprint coming online, I have increasing confidence in our ability to accelerate performance through 2026, to remain on track toward our goal of over $250 million in quarterly revenue by the end of 2027."

He's looking even further ahead too: "And that won't be the end of the story because beginning in 2028, we intend to further leverage our commercial platform by launching late-stage, large market assets in development, like G-MELT (formerly MELT-300), YOCHIL (formerly MELT-210), a next-generation TRIESENCE pre-filled syringe, and other high-impact product candidates in other phases of review."

Baum expressed confidence in the company's ability to deliver positive surprises with several products in development, emphasizing a commitment to transparency in financial guidance moving forward.

Here's the thing about CEO optimism: investors have heard it before. What they're reacting to today are the actual numbers—the earnings miss and the guidance that suggests growth might be slower than expected. When a CEO says "trust me, good things are coming" but the numbers say "actually, maybe not as quickly as we thought," the market tends to believe the numbers.

The Technical Picture: Not Pretty

If you look at the charts, they're telling the same story as the fundamentals. The stock is currently trading 14.76% below its 20-day simple moving average and 12.34% below its 100-day SMA. That's what technicians call a bearish trend. Over the past 12 months, shares have decreased significantly, and they're currently positioned closer to their 52-week lows than highs.

The RSI (Relative Strength Index) is at 44.45, which is considered neutral territory—neither overbought nor oversold. Meanwhile, the MACD (Moving Average Convergence Divergence) is at 0.15, below its signal line at 0.22, indicating bearish pressure on the stock.

The combination of neutral RSI and bearish MACD suggests mixed momentum, which basically means traders should watch for potential volatility in the near term. If you're looking for levels to watch, key resistance sits at $54.50, while key support is at $20.85.

As of premarket trading on Tuesday, Harrow shares were down 12.32% at $46.99. That's a significant move for one day, especially when you consider the stock has already been trending downward.

So what's an investor to make of all this? You've got a company that's growing revenue but missing earnings, guiding below expectations but promising big things in the future, and a stock that's technically broken down but not yet in oversold territory. It's the kind of situation where you need to decide whether you believe management's long-term vision or the market's short-term reaction. Today, at least, the market is voting with its sell orders.